Needham Maintains Buy on Cardlytics, Raises Price Target to $17
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Kyle Peterson has maintained a Buy rating on Cardlytics (NASDAQ:CDLX) and increased the price target from $15 to $17.
April 09, 2024 | 11:34 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Kyle Peterson reaffirmed a Buy rating on Cardlytics and raised the price target from $15 to $17.
The increase in the price target by a reputable analyst suggests a positive outlook on Cardlytics' future performance. This endorsement is likely to instill confidence in investors, potentially driving up the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100